S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
S&P 500   4,410.13 (+0.28%)
DOW   34,364.50 (+0.29%)
QQQ   353.30 (+0.46%)
AAPL   161.62 (-0.49%)
MSFT   296.37 (+0.11%)
FB   308.71 (+1.83%)
GOOGL   2,616.08 (+0.35%)
AMZN   2,890.88 (+1.33%)
TSLA   930.00 (-1.47%)
NVDA   233.72 (+-0.01%)
BABA   120.37 (-2.32%)
NIO   24.87 (-9.07%)
AMD   116.53 (-1.92%)
CGC   7.40 (+1.51%)
MU   82.95 (+1.24%)
GE   96.91 (+0.63%)
T   26.34 (-1.01%)
F   20.39 (-1.26%)
DIS   137.46 (+0.06%)
AMC   16.64 (-7.40%)
PFE   51.54 (-2.37%)
ACB   4.32 (-3.14%)
BA   204.20 (-0.60%)
OTCMKTS:ARFXF

ProMIS Neurosciences Stock Forecast, Price & News

$0.10
0.00 (-3.92%)
(As of 01/24/2022 03:13 PM ET)
Add
Compare
Today's Range
$0.10
$0.11
50-Day Range
$0.09
$0.14
52-Week Range
$0.07
$0.23
Volume
130,050 shs
Average Volume
287,622 shs
Market Capitalization
$44.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.11
30 days | 90 days | 365 days | Advanced Chart
Receive ARFXF News and Ratings via Email

Sign-up to receive the latest news and ratings for ProMIS Neurosciences and its competitors with MarketBeat's FREE daily newsletter.


ProMIS Neurosciences logo

About ProMIS Neurosciences

ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.

Headlines

ProMIS Neurosciences (OTCMKTS:ARFXF) Stock Price Down 2%
January 8, 2022 |  americanbankingnews.com
ProMIS Neurosciences Files Special Meeting Proxy Material
October 21, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ARFXF
CIK
N/A
Fax
N/A
Employees
147,000
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Net Income
$-4.23 million
Pretax Margin
-188,900.00%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$44.47 million
Optionable
Not Optionable

Company Calendar

Today
1/24/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












ProMIS Neurosciences (OTCMKTS:ARFXF) Frequently Asked Questions

Who are ProMIS Neurosciences' key executives?

ProMIS Neurosciences' management team includes the following people:
  • Eugene Williams, Chairman & Chief Executive Officer
  • Elliot Goldstein, President & Director
  • Gavin T. Malenfant, Chief Operating Officer
  • Daniel E. Geffken, Chief Financial Officer
  • Neil R. Cashman, Director & Chief Scientific Officer

What is ProMIS Neurosciences' stock symbol?

ProMIS Neurosciences trades on the OTCMKTS under the ticker symbol "ARFXF."

How do I buy shares of ProMIS Neurosciences?

Shares of ARFXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProMIS Neurosciences' stock price today?

One share of ARFXF stock can currently be purchased for approximately $0.10.

How much money does ProMIS Neurosciences make?

ProMIS Neurosciences has a market capitalization of $44.47 million. The company earns $-4.23 million in net income (profit) each year or ($0.02) on an earnings per share basis.

How many employees does ProMIS Neurosciences have?

ProMIS Neurosciences employs 147,000 workers across the globe.

What is ProMIS Neurosciences' official website?

The official website for ProMIS Neurosciences is www.promisneurosciences.com.

Where are ProMIS Neurosciences' headquarters?

ProMIS Neurosciences is headquartered at 1920 Yonge Street Suite 200Suite 200, Toronto A6, M4S 3E2.

How can I contact ProMIS Neurosciences?

ProMIS Neurosciences' mailing address is 1920 Yonge Street Suite 200Suite 200, Toronto A6, M4S 3E2. The company can be reached via phone at (416) 847-6898.


This page was last updated on 1/24/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.